Sidiq Zeeshan, Hanif M, Dwivedi Kaushal Kumar, Chopra K K
New Delhi Tuberculosis Centre, JLN Marg, New Delhi, India.
New Delhi Tuberculosis Centre, JLN Marg, New Delhi, India.
Indian J Tuberc. 2020 Dec;67(4S):S128-S131. doi: 10.1016/j.ijtb.2020.09.023. Epub 2020 Oct 1.
In December 2019 a novel coronavirus SARS-CoV-2 emerged in the Hunan seafood market in Wuhan, China, and soon became a global health problem. Since its outbreak, SARS-CoV-2 has had a major impact on clinical diagnostic laboratories. The scientific community has quickly risen to the occasion and reports of new developments have arrived at an unprecedented scale. At present, there is a growing list of over 400 SARC-CoV-2 diagnostic tests either in development or approved for clinical use. This presentation reviews the current laboratory methods available for testing COVID- 19 in microbiology laboratories and also provides an insight into the future diagnostics approaches.
Proper respiratory specimen collected at the appropriate time and from the right anatomical site is critical in the accurate and timely diagnosis of SARSCoV2. While oropharyngeal and nasopharyngeal swabs are recommended for the detection of early infection, other lower respiratory tract specimens like the sputum and bronchoalveolar lavage are used for late detection and monitoring of patients with severe COVID-19 pneumonia.
Real-time RT-PCR based molecular assay remains the test of choice for the etiological diagnosis of SARS-CoV-2 while serological tests are being introduced as supplementary tools. Finally, there is an urgent need for scaling up the diagnostic capacity by the introduction of reliable and accurate point-of-care tests which will assist in effective control of this outbreak. These assays can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.
2019年12月,一种新型冠状病毒SARS-CoV-2在中国武汉的华南海鲜市场出现,并很快成为一个全球健康问题。自爆发以来,SARS-CoV-2对临床诊断实验室产生了重大影响。科学界迅速应对,新进展的报告达到了前所未有的规模。目前,正在研发或已获临床使用批准的SARS-CoV-2诊断测试越来越多,已超过400种。本报告回顾了微生物实验室目前可用于检测2019冠状病毒病的实验室方法,并对未来的诊断方法进行了展望。
在适当的时间从正确的解剖部位采集合适的呼吸道标本,对于准确及时诊断SARS-CoV-2至关重要。虽然推荐使用口咽拭子和鼻咽拭子检测早期感染,但对于严重的2019冠状病毒病肺炎患者的晚期检测和监测,则使用痰液和支气管肺泡灌洗等其他下呼吸道标本。
基于实时逆转录聚合酶链反应的分子检测仍然是SARS-CoV-2病原学诊断的首选检测方法,而血清学检测正作为补充工具被引入。最后,迫切需要通过引入可靠且准确的即时检测来扩大诊断能力,这将有助于有效控制此次疫情。这些检测方法可用于承担识别和治疗患者重任的当地医院和诊所。